Artelo Biosciences, Inc.
ARTL
$7.20
$0.11021.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 995.00K | 1.34M | 870.00K | 827.00K | 1.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.38M | 3.81M | 1.20M | 2.51M | 2.59M |
| Operating Income | -2.38M | -3.81M | -1.20M | -2.51M | -2.59M |
| Income Before Tax | -2.37M | -3.78M | -1.13M | -2.43M | -2.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.37M | -3.78M | -1.13M | -2.43M | -2.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.37M | -3.78M | -1.13M | -2.43M | -2.48M |
| EBIT | -2.38M | -3.81M | -1.20M | -2.51M | -2.59M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -5.06 | -8.13 | -2.45 | -5.28 | -5.44 |
| Normalized Basic EPS | -3.16 | -5.13 | -1.62 | -3.40 | -3.54 |
| EPS Diluted | -5.06 | -8.13 | -2.45 | -5.28 | -5.44 |
| Normalized Diluted EPS | -3.16 | -5.13 | -1.62 | -3.40 | -3.54 |
| Average Basic Shares Outstanding | 3.83M | 3.80M | 3.77M | 3.77M | 3.73M |
| Average Diluted Shares Outstanding | 3.83M | 3.80M | 3.77M | 3.77M | 3.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |